Swedish biotech doses first subjects in new ATR-258 study, betting that the next big obesity breakthrough will be about protecting muscle.
Swedish clinical-stage biotech Atrogi has dosed the first subjects in a new human trial of ATR-258, its lead oral drug candidate, marking a fresh milestone for a biotech company trying to answer one of the most urgent questions in metabolic medicine: can you help people lose fat without sacrificing muscle?
The current obesity-drug boom has changed the conversation around weight loss. Yet as powerful new therapies have moved into the mainstream, so has a more complicated reality: not all weight loss is equal. When the number on the scale drops, some of what disappears can be muscle and for older adults, that can mean less strength, lower resilience and a harder road to healthy aging.
Atrogi wants to position ATR-258 on the other side of that problem. The Stockholm-based biotech announced that the first participants have now been dosed in an 8-week, investigator-initiated interventional study evaluating the effects of ATR-258 on muscle in overweight male volunteers [1]. The drug is designed as an oral therapy that aims to mimic some of the metabolic and muscle-related effects of exercise.
If that sounds ambitious, it is, but it also lands squarely in one of the most compelling investment narratives in longevity today. Body composition is becoming more important than body weight alone.
Atrogi is eager to introduce a pill that aims to do more than just trim pounds. The company describes ATR-258 as a first-in-class oral therapy with the potential to drive fat loss, increase muscle and improve metabolism.
Instead of simply telling the body to eat less or store less, ATR-258 is designed to nudge muscle tissue to act more like it does during exercise, burning fuel more efficiently and preserving the lean tissue that keeps us strong.
Rather than looking only at whether people lose weight, researchers are trying to understand whether ATR-258 can influence the quality of that weight loss. In other words, can it help the body keep the “good stuff” while shedding the excess?
Muscle is one of the best predictors of how well people age. It supports mobility, glucose control, balance, recovery and independence. Losing fat can improve health. Losing muscle at the same time can quietly undermine it.
Why does Atrogi think this approach is different? The study is being led by Associate Professor Morten Hostrup of the University of Copenhagen, who will examine how ATR-258 affects human skeletal muscle through daily oral dosing over eight weeks.
“This trial will allow us to rigorously interrogate targeted downstream effector signaling associated with the β2-adrenergic receptor in human skeletal muscle using a highly selective next generation modulator,” said Hostrup.
The team wants to see whether this more targeted drug can activate muscle-building and metabolic pathways in a precise way, rather than blasting the whole system and causing unwanted side effects.
Hostrup added that the goal is to understand how the approach could be used “to preserve, or even augment, muscle function in various conditions of muscle wasting, such as immobilization, aging and weight loss.”
That list is where the story widens. This is not just an obesity drug thesis. It is also a muscle-health thesis, and that opens the door to a broader longevity conversation around frailty, sarcopenia and the slow erosion of physical function that often defines later life more than any single disease.
Atrogi says the trial builds on momentum from a June 2025 Cell publication validating its platform, as well as first-in-human Phase 1 data in 69 subjects showing ATR-258 was safe and well-tolerated in healthy volunteers and patients with type 2 diabetes.
Professor Tore Bengtsson, the founder and chief scientific officer of Atrogi, expressed excitement about Hostrup’s commitment to investigating the muscle-signaling effects of ATR-258. He noted that Hostrup is a widely recognized expert in the field and that this new research will build upon findings published in Cell in June 2025.
Professor Tore Bengtsson is the founder and chief scientific officer of Atrogi
Bengtsson further remarked that Hostrup’s decision to sponsor the study validates the strength of Atrogi’s science and technology, adding that the company expects to share the results later this year.
Paul Little, chief executive officer of Atrogi, called the first dosing “an important milestone” and said the resulting muscle physiology data will help support the drug’s development across “metabolic and muscle-wasting conditions.”
Investors should keep the caveats in view. This is still early-stage biotech, and “exercise mimetics” have long been among the industry’s most seductive yet difficult ideas. A promising mechanism is not the same thing as clinical success. A carefully designed human study is not the same as proof that patients will gain a durable, meaningful benefit.
Still, Atrogi’s timing looks smart. The obesity market is maturing. The first wave rewarded therapies that helped people lose weight fast. The next wave may reward therapies that help people lose better – preserving muscle, improving function and making metabolic health more sustainable over decades, not just quarters.
That is where it becomes a longevity story. The most interesting companies in this space are asking a harder, more useful question: how do we help people stay strong enough to enjoy the years they already have? For now, Atrogi has taken a small but meaningful step toward answering that.